Articles related to CARDIOVASCULAR EVENTS

Clinical research demonstrates that erythritol consumption increases blood levels by more than 1,000 times and enhances platelet responsiveness in healthy volunteers, potentially elevating cardiovascular risk in susceptible populations.

In a comprehensive Bayesian network meta-analysis, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a significant reduction in major bleeding compared to the conventional 12 months of DAPT, without an increase in MACCE.

Bempedoic acid reduced major adverse cardiovascular events by 13% compared to placebo in statin-intolerant patients, with efficacy comparable to statins when normalized for LDL-C reduction.

The ABYSS trial questions the safety of interrupting long-term beta-blocker treatment in patients with a history of uncomplicated myocardial infarction, finding that discontinuation was not noninferior to continuation.

Extraosseous calcification in chronic and end-stage kidney disease involves a complex pathogenesis, impacting patient morbidity and mortality through vascular, soft tissue, and calciphylaxis manifestations.

Recent findings indicate that statin-naïve ACS patients with normal LDL-C levels at admission may face worse outcomes, challenging current perspectives on lipid management in cardiovascular care.